SAN DIEGO / Apr 05, 2023 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which provides updates on key environmental, social, and governance (ESG) initiatives that are aligned with Dexcom’s core values and business strategy.
“At Dexcom, we recognize and value the significant trust placed in our company not only by our global customer base, but also our employees and their families, our communities and our shareholders,” said Kevin Sayer, chairman, president and CEO of Dexcom. “We believe that by advancing the interests of our key stakeholders, we can both support the success of our business and drive greater health and economic benefits for our users and global health systems.”
Dexcom’s sustainability initiatives are integrated as foundational elements of the company’s core values and business strategy. The annual report is once again framed according to the company’s four core values: Listen, Think Big, Be Dependable, and Serve with Integrity.
Highlights from this year’s report include:
Dexcom’s annual Sustainability Report can be found on the company’s investor relations site at the following link: Dexcom Sustainability Report. All data in the report reflects fiscal year 2022, unless noted otherwise.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
Last Trade: | US$124.34 |
Daily Change: | -13.67 -9.91 |
Daily Volume: | 8,547,988 |
Market Cap: | US$47.940B |
April 25, 2024 February 08, 2024 January 08, 2024 December 19, 2023 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB